Member Info for Foxykiwi

next year will stop RR from posting anticipated profits, so a no no for me.

Horse, the shareprice went stratospheric, not because of any RNS, but poor p.i demand on the back of poor pi assumptions. Too many were sucked in by the "Oh I went into Superdrug..blah blah", "Sold out in stores blah blah" and clouded minds while the P/E went something short of Apple, so the fall was expected and hard. RNS will dictate SP now not muppet p.i's who think they knwo more than the company

"Oh I went into Superdrug...blah blah" schoolboys. I enjoyed the humour while wondering why P/E was going into stupid territory.

wake up boy and smell the American Business

to top on before results. Still read the last RNS in Nov, so very lucky to build a postion at these prices CPPGroup Plc ("CPP" or "the Group"), the international assistance business, today provides an update on trading in the period since the Group's interim results announcement published on 18 August 2016 (the "Interim Results"). A combination of continued focus on cost control across the Group, increased sales volumes in our Indian business, and the impact of a weaker sterling on the results of our European operations, has resulted in the Board now anticipating underlying operating profit1 for the full year ended 31 December 2016 to be materially ahead of the expectations detailed in the Interim Results. Additionally, further to the Group's announcement on 14 September 2016, regarding the decision to develop an IT platform on its existing systems, CPP continues to negotiate an agreement with SSP Limited and will provide an update on the final outcome in due course.

high swings in SP and spread for such a small cap stock

Already heard about this last year. Impact is minimal when considering how many people actually fill in forms compared to doing it online. Other countries??? Big BUY for me!!!

Just invested after research but can fnd any reason for the fall.. Anyone?

Our new deep dive into Hikma's medium term pipeline and long term opportunities gives us increased confidence. While it doesn't change the near term trajectory, it points to a pathway for sustained growth and should lead to a multiple re-rating. Top down: significant opportunities remain in the broader market for Hikma. We worked our way down from the 800+ drug list of pending generic filings and found that Hikma is well placed to capitalise long term. A third of this list are Central Nervous System drugs, an area the company has expertise in. We estimate a further combined value of $750m comes from scheduled and extended release drugs, two areas Hikma has been explicit in targeting. While we do not know if Hikma is behind these specific filings, these areas represent the generic opportunity set where Hikma is well placed and likely to pursue, providing a healthy LT pipeline. Valuation attractive: in-line with EU Pharma does not reflect LT growth prospects. With Hikma trading at 15x 2017e earnings, a substantial discount to history, we see limited downside near-term. The stock has underperformed by 19% over the past 3 months; we see upside as we view the stock as oversold (DoJ investigation (see here), sector de-rating) and believe the CMD Nov 15th could bring incremental upside with visibility. Hikma's 17% earnings growth CAGR (17- 19e) supports our belief that Hikma deserves to trade at a premium.

www.marketslant.com/articles/golds-headed-1850-election-determines-how

Seems a well balanced company from the heedy speed it grew over the year. Westward still got ??? on it. But overall Im pleased

Hold for trading stmt in Nov. Brokers still positive (even though who believes brokers). Any positive news with merger will boost sp. Bottomline has got market worried, but Director purchases in the millions does encourage.

Seems confidence in the Directors is extremely high and Mr Market hasn't caught on yet

yep

RNS is required here to confirm reason for movement. Seems obvious with larger % gain

Expect this to boost underline figures for FY for stocks like these. Also not one SELL note Brokers, but they are rubbish anyway. Love active stocks even if I am down a bit

let Mr Market manipulate this down and shake the stock and why not until Interims are due in a couple of weeks. Im spread on this at £15 per point on average 2250. Down but not out

see Bloomberg Interview today and takeover news

probable de-lisitng like some other rusky quoted stocks.

Ophir has signed a non-binding Heads of Terms Agreement with Schlumberger whereby Schlumberger will, subject to due diligence, definitive documentation and Government approval, receive a 40% economic interest in the Fortuna FLNG project, offshore Equatorial Guinea. Ophir and Schlumberger will now work towards signing a definitive agreement, which is expected to be signed in 2Q 2016, ahead of Final Investment Decision. Under the definitive agreement Schlumberger will reimburse 50% of Ophir's past costs in the form of a development carried interest. This is expected to cover Ophir's share of capital expenditures up until first sales of LNG.